Literature DB >> 3159791

Tumor-promoting phorbol esters induce rapid internalization of the C3b receptor via a cytoskeleton-dependent mechanism.

J J O'Shea, E J Brown, T A Gaither, T Takahashi, M M Frank.   

Abstract

Plasma membrane expression as well as phagocytic capability of the C3b receptor (CR1) are under regulatory control. Phorbol esters are one class of agents which have been shown to influence both of these events. In this study, by using radiolabeled Fab fragments of a monoclonal anti-CR1 antibody to tag the receptor and acid elution of surface-bound Fab, we showed that both phorbol myristate acetate and phorbol dibutyrate induced internalization of the C3b receptor; this occurred in a dose- and time-dependent manner in the absence of occupancy of the receptor by ligand. This was shown to occur in neutrophils, monocytes, and macrophages. We also showed that phorbol esters enhanced CR1-dependent phagocytosis despite the presence of two-thirds fewer receptors present on the plasma membrane. However, fibronectin, another agent that influences phagocytosis, had no effect on receptor internalization. Phorbol ester internalization was temperature-dependent and was inhibitable by cytochalasins B and D. Inhibition of internalization was reversible when cytochalasin B was removed. Phorbol esters also induced increased detergent insolubility of CR1 with kinetics similar to those of receptor internalization. It is possible that association of CR1 with the cytoskeleton is important to the process of "activation" of CR1 in phagocytosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3159791

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Characterization and cytoskeletal association of a major cell surface glycoprotein, GP 140, in human neutrophils.

Authors:  S J Suchard; L A Boxer
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

2.  Internalization pathway of C3b receptors in human neutrophils and its transmodulation by chemoattractant receptors stimulation.

Authors:  J L Carpentier; D P Lew; J P Paccaud; R Gil; B Iacopetta; M Kazatchkine; O Stendahl; T Pozzan
Journal:  Cell Regul       Date:  1991-01

3.  Effects of chemotactic peptide f-Met-Leu-Phe (FMLP) on C3b receptor (CR1) expression and phagocytosis of microspheres by human neutrophils.

Authors:  J D Ogle; J G Noel; R M Sramkoski; C K Ogle; J W Alexander
Journal:  Inflammation       Date:  1990-06       Impact factor: 4.092

4.  Interactions of monomeric IgG bearing covalently bound C3b with polymorphonuclear leucocytes.

Authors:  A Malbran; M M Frank; L F Fries
Journal:  Immunology       Date:  1987-05       Impact factor: 7.397

5.  Leukocyte adhesion-deficient neutrophils fail to amplify phagocytic function in response to stimulation. Evidence for CD11b/CD18-dependent and -independent mechanisms of phagocytosis.

Authors:  H D Gresham; I L Graham; D C Anderson; E J Brown
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

6.  Presence of serum modulates expression of complement receptor type 1 (CR1) on human granulocytes after quartz exposure.

Authors:  J Lundahl; A Eklund; J Hed; G Tornling; M Vitas
Journal:  Inflammation       Date:  1993-08       Impact factor: 4.092

7.  Cell surface expression of fMet-Leu-Phe receptors on human neutrophils. Correlation to changes in the cytosolic free Ca2+ level and action of phorbol myristate acetate.

Authors:  T Andersson; C Dahlgren; P D Lew; O Stendahl
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

8.  CR1-receptor recycling in phorbol ester-activated polymorphonuclear leucocytes.

Authors:  A Malbran; S Siwik; M M Frank; L F Fries
Journal:  Immunology       Date:  1988-02       Impact factor: 7.397

9.  C3b receptor (CR1) expression on the polymorphonuclear leukocytes from patients with systemic lupus erythematosus.

Authors:  A Fyfe; E R Holme; A Zoma; K Whaley
Journal:  Clin Exp Immunol       Date:  1987-02       Impact factor: 4.330

10.  Serum protects against azurophil granule dependent down-regulation of complement receptor type 1 (CR1) on human neutrophils.

Authors:  J Lundahl; C Dahlgren; K Gustavsson; J Hed
Journal:  Inflamm Res       Date:  1995-10       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.